Pilmis B, et al. - This study appraised β-lactam/β-lactamase inhibitor combinations (BL/BLIs), such as piperacillin–tazobactam, as alternatives to carbapenems for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE)-related infections in ICU patients. Caution was recommended with respect to the use of piperacillin–tazobactam for treating ICU patients with ESBL-PE-related infections. Data also recommended avoiding BL/BLI empirical use for therapy of ESBL-PE-related infection. Notably, definitive therapy should be reserved to patients in clinical stable condition, after microbial documentation and results of susceptibility tests. In order to reach pharmacological targets, optimization of administration and use of higher dosage were recommended.